Trial Profile
Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms STEP 5
- Sponsors Novo Nordisk
- 24 Aug 2023 Results assessing effect of semaglutide on 10-year type 2 diabetes risk in adults with overweight or obesity in STEP1 & STEP 5 studies, published in the Obesity (Silver Spring, Md.)
- 01 Oct 2022 Results assessing efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, published in the Nature Medicine.
- 23 Sep 2022 Results of post hoc analysis assessing Impact of once weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.